Shark IgNAR: The Next Broad Application Antibody in Clinical Diagnoses and Tumor Therapies? [PDF]
Marine Drugs, 2023 Antibodies represent a relatively mature detection means and serve as therapeutic drug carriers in the clinical diagnosis and treatment of cancer—among which monoclonal antibodies (mAbs) currently occupy a dominant position.
Xiaofeng Jiang +5 more
doaj +2 more sources
Generation of shark single-domain antibodies as an aid for Cryo-EM structure determination of membrane proteins: Use hyaluronan synthase as an example [PDF]
Journal of Structural Biology: XIn cartilaginous fish, the immunoglobulin new antigen receptor (IgNAR) is naturally devoid of light chains. The variable regions of IgNAR (VNARs) are solely responsible for antigen recognition, similar to VHHs (variable domain of the heavy chain of heavy-
Penghui Deng +6 more
doaj +2 more sources
Novel, Anti-hTNF-α Variable New Antigen Receptor Formats with Enhanced Neutralizing Potency and Multifunctionality, Generated for Therapeutic Development [PDF]
Frontiers in Immunology, 2017 The management of chronic inflammatory diseases, such as inflammatory bowel disease, psoriasis, and rheumatoid arthritis has significantly improved over the last decade with the clinical availability of anti-TNF-α biologics.
Obinna C. Ubah +7 more
doaj +4 more sources
The characterization of variable new antigen receptors targeting FAP isolated from a novel immunized library [PDF]
Communications BiologyCancer-associated fibroblasts (CAFs) in the stroma of solid tumors promote an immunosuppressive tumor microenvironment (TME) that drives resistance to therapies.
Gihan S. Gunaratne +15 more
doaj +2 more sources
Screening and characterization of inhibitory vNAR targeting nanodisc-assembled influenza M2 proteins
iScience, 2023 Summary: Influenza A virus poses a constant challenge to human health. The highly conserved influenza matrix-2 (M2) protein is an attractive target for the development of a universal antibody-based drug.
Chuandi Yu +26 more
doaj +3 more sources
In Vitro Maturation of a Humanized Shark VNAR Domain to Improve Its Biophysical Properties to Facilitate Clinical Development [PDF]
Frontiers in Immunology, 2017 Molecular engineering to increase the percentage identity to common human immunoglobulin sequences of non-human therapeutic antibodies and scaffolds has become standard practice.
John Steven +11 more
doaj +4 more sources
Synthetic libraries of shark vNAR domains with different cysteine numbers within the CDR3.
PLoS ONE, 2019 The variable domain of New Antigen Receptors (vNAR) from sharks, present special characteristics in comparison to the conventional antibody molecules such as: small size (12-15 kDa), thermal and chemical stability and great tissue penetration, that makes
Olivia Cabanillas-Bernal +5 more
doaj +4 more sources
The structural basis for the selective antagonism of soluble TNF-alpha by shark variable new antigen receptors [PDF]
Nature CommunicationsThe pro-inflammatory cytokine tumor necrosis factor-alpha (TNF-α) is synthesized as transmembrane TNF-α (tmTNF-α) where proteolytic processing releases soluble TNF-α (sTNF-α).
Obinna C. Ubah +13 more
doaj +2 more sources
Specific Targeting of Lymphoma Cells Using Semisynthetic Anti-Idiotype Shark Antibodies [PDF]
Frontiers in Immunology, 2020 The B-cell receptor (BCR) is a key player of the adaptive immune system. It is a unique part of immunoglobulin (Ig) molecules expressed on the surface of B cells. In case of many B-cell lymphomas, the tumor cells express a tumor-specific and functionally
Arturo Macarrón Palacios +8 more
doaj +3 more sources
Unleashing the power of shark variable single domains (VNARs): broadly neutralizing tools for combating SARS-CoV-2 [PDF]
Frontiers in Immunology, 2023 The pandemic caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) generated a joint global effort to develop vaccines and other treatments that could mitigate the negative effects and the rapid spread of the virus.
Olivia Cabanillas-Bernal +4 more
doaj +2 more sources